



03 April 2023

AIM: RENE

**ReNeuron Group plc
("ReNeuron" or the "Company")**

New Scientific Advisory Board

ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome technologies, announces the appointment of Prof. Giuseppe (Beppe) Battaglia, Prof. Edit I Buzás, Prof. Dr. rer. Nat. Bernd Giebel and Prof. Kenneth W. Witwer to a newly established Scientific Advisory Board (SAB), chaired by Prof. Stefano Pluchino.

This new SAB, composed of leading academics and industry executives, brings a world-class breadth of expertise across the extracellular vesicle (EV) field. Its role is to advise the Company on scientific matters relating to its exosome platform research and development strategy.

For additional information on ReNeuron's Scientific Advisory Board and its members, please visit the Company's website via the following link: <https://www.reneuron.com/about-us/advisory-board/>.

Stefano Pluchino, Chair of the SAB, commented: "I am delighted that we have attracted such renowned EV experts to join the ReNeuron SAB and it is a privilege to be the Chair of the board. I very much look forward to working alongside them and the Company as we seek to progress the development of the Company's stem cell-derived exosome-based drug delivery platform.

"On behalf of the Company, I would also like to take the opportunity to thank the former members of the old Scientific Advisory Board for all the advice and support provided during their membership."

ENDS

Enquiries:

ReNeuron

Iain Ross, Executive Chairman
John Hawkins, Chief Financial Officer

www.reneuron.com/investors

Via Walbrook PR

Allenby Capital Limited (Nominated Adviser and Broker)

James Reeve/George Payne (Corporate Finance)
Stefano Aquilino (Sales & Corporate Broking)

+44 (0)20 3328 5656

Walbrook PR (Media & Investor Relations)

Paul McManus / Alice Woodings

+44 (0)20 7933 8780 or reneuron@walbrookpr.com

+44 (0)7980 541 893 / +44 (0)7407 804 654

About ReNeuron

ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities.

Through the generation of several unique and scalable exosome producer cell lines, our CustomEX™ platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, the Company can make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.

ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com